Clinical or radiographic evidence of metastatic disease; metastatic workup is not required, but is recommended for patients with clinical stage III disease; Note: isolated ipsilateral supraclavicular node involvement is permitted
Patients with evidence of metastatic disease involvement in viscera or bone
Radiographic evidence of intratumor cavitation.
Patients with evidence of myelodysplasia
Evidence of other immune related disease /conditions.
Evidence or high suspicion of metastatic disease at enrollment
No evidence of extrahepatic metastatic disease
Pathologically confirmed squamous cell carcinoma of the head and neck with evidence of metastatic disease or locally recurrent disease considered incurable by local therapies; patients without pathologic or cytologic evidence of metastatic disease should have unequivocal evidence of metastasis from physical examination or radiologic evaluation
Histologic evidence of DDLS at any time prior to randomization AND current evidence of DDLS requiring treatment
Pathologically proven, radiologic or clinical evidence of distant metastatic disease (this includes all disease below the clavicles, as well as disease metastatic to the bone, brain, or in the spinal canal)
Patient has evidence of metastatic disease
Evidence of metastatic disease
TREATMENT WITH SJCAR: Evidence of active, uncontrolled neurologic disease
Has evidence of metastatic disease at time of diagnosis.
Evidence of metastatic disease
No evidence of metastatic disease as determined by imaging procedures.
Documented evidence of active acromegaly
Radiographic evidence of metastatic disease
Unequivocal evidence of metastatic disease defined by computerized tomography (CT) (includes resectable metastases)
Evidence of metastatic disease.
Clinically no evidence of local, regional, or metastatic disease at the time of study entry
Cross-sectional imaging evidence of progression of recurrent/metastatic disease
Clinically node negative, no evidence of metastatic disease
Radiographic evidence of metastatic disease
Evidence of metastatic disease that is extensive enough to preclude consideration of subsequent definitive surgery for the primary tumor
Clinical evidence of progression of disease > % in the breast or new evidence of nodal metastases
Known evidence of active cerebral/meningeal CLL; patients may have a history of central nervous system (CNS) leukemic involvement if definitively treated with prior therapy and no evidence of active disease at the time of registration (defined as >=  consecutive spinal fluid assessments with no evidence of disease)
No evidence of hydronephrosis
Evidence of disease by standard morphologic or by minimal residual disease (MRD) criteria
Diagnosis of widespread visceral and/or osseous metastatic disease based on clinical and radiographic evidence; (patients may continue on study if surgery shows a non-malignant process)
Participants with LL must have radiographic evidence of disease
Absence of radiographic evidence of extrathyroidal extension
Evidence of ischemic heart disease as determined by study cardiologist
Evidence of metastatic disease
Known evidence of active cerebral/meningeal disease; patients may have history of central nervous system (CNS) leukemic involvement if definitively treated with prior therapy and no evidence of active disease (defined as >=  consecutive spinal fluid assessments with no evidence of disease) at that time of registration
Evidence of hemachromatosis.
Evidence of metastatic disease
No evidence of metastatic disease
No clinical or radiological evidence of metastatic disease or local progression
Any evidence of metastatic disease
M stage based on no evidence of metastatic disease by CT imaging.
Evidence of other immune related disease/conditions.
Clinical evidence or known history of cardiopulmonary disease
Evidence of metastatic disease
Patients with clinical evidence of metastatic disease.
Evidence of ischemic heart disease as determined by study cardiologist
Prior evidence of p/q co-deletion
Patients with evidence of extraneural disease
Patients with evidence of metastatic disease involvement in viscera or bone
Radiographic evidence of metastatic disease
Clinical, radiographic or pathologic evidence of multicentric disease
No evidence of metastatic disease by clinical and radiological staging
Evidence or suspicion of disease metastatic to sites remote from the supratentorial brain
Patients must have evidence of metastatic disease (non measurable disease is eligible)
Radiological evidence of metastatic disease
Patients with evidence of metastatic disease outside of the pelvis
Evidence of metastatic disease outside of the abdomen
Evidence of metastatic disease outside of the abdomen
Current or previous evidence of muscle invasive (muscularis propria) or metastatic disease presented at the screening visit. Examples that increase the risk of metastatic disease are (but not limited to):
Patient with documented evidence of metastatic disease
Prior or present evidence of distant metastatic disease as assessed by radiographic imaging;
No prior or present evidence of metastatic disease;
Evidence of metastatic disease or nodal disease outside the prostate on bone scan or cross-sectional imaging.
Patients must have no evidence of muscle invasive disease
Evidence of metastatic disease on cross sectional imaging or bone scan
Clinical or radiographic evidence of metastatic disease; metastatic workup is not required\r\n* Note: isolated ipsilateral supraclavicular node involvement is permitted
Evidence of extrauterine spread of disease on imaging or during surgical evaluation
Definite evidence of metastatic disease
There is no evidence of disease relapse at the time of screening, and minimal residual disease (MRD) is acceptable
Evidence of metastatic disease
No evidence of disease at the time of registration, including no clinical concern for disease recurrence based on each of the following:\r\n* No evidence of disease by history and physical exam\r\n* Cancer antigen (CA) within normal limits\r\n* Computed tomography (CT) abdomen/pelvis demonstrating no radiological evidence of disease performed after completion of chemotherapy =<  days before entering study
Evidence of metastatic disease
Patients must not have evidence of metastatic tumor or other cancer
Patients with central nervous system disease are eligible for enrollment if they have received prior radiotherapy or surgery to sites of CNS metastatic disease and are without evidence of clinical progression for at least  weeks prior to screening, have no evidence of new or enlarging brain metastases, and are off steroids for at least  days before first dose of pembrolizumab.
No evidence of disease by standard morphology; minimal residual disease or molecular evidence of disease will not exclude
Currently have no clinical evidence of disease
No evidence of extranodal metastatic disease
Patients must not have intra-operative evidence of Tb disease
Resectable primary tumor with no evidence of metastatic disease by imaging. Imaging must be performed within  days of Day  of study.
CT or MRI evidence of metastatic disease to the bone
Evidence of extrauterine spread of disease on imaging or during surgical evaluation
Patients with only locally or regionally confined disease without evidence of metastatic disease
No evidence of metastatic disease
Evidence or suspicion of disease metastatic to sites remote from supratentorial brain
Clinical (e.g. multiple new cranial nerve deficits in the absence of obvious radiographic disease to explain symptoms) or radiographic evidence of leptomeningeal disease
Has a prior history or current evidence of intracranial (CNS) metastatic RCC, except for ? lesions treated by CyberKnife or excisional surgery, clinically stable for at least  weeks, and without evidence of recurrence on MRI imaging at screening.
Evidence of nephrectomy
Radiographic evidence of disease
Participants with evidence of non-hepatic metastatic disease
No evidence of known metastatic disease (M or Mx allowed)
Evidence of significant hepatic, hematologic, or immunologic disease.
Presence of distant metastatic disease; patients will undergo radiographic evaluation to exclude the possibility of distant metastatic disease; for patients who have undergone pre- or postoperative biopsies that definitively diagnose ICC, the diagnostic studies may be modified at the discretion of the MSKCC principal investigator; clinical or radiographic evidence of metastatic disease to regional lymph nodes will be allowed, provided it is amenable to resection
Completely resected hepatic metastases without current evidence of other metastatic disease
Radiographic evidence of disease
Radiographic evidence measurable of residual or metastatic disease after surgery
Evidence of metastatic disease on imaging studies
No evidence of disease
Clinical evidence of metastatic disease
Have no current evidence of disease
Survivors must not have evidence of recurrent or metastatic disease
Evidence of complete response at three months post-treatment; maintenance therapy is permitted as long as there is no evidence of disease
Patients seen in the SCC with a diagnosis of cancer with or without evidence of metastatic disease
No known evidence of disease
Have no evidence of recurrence or metastatic disease
Patients with evidence of muscle-invasion or metastatic disease will be excluded
Patients who currently have no evidence of disease
Evidence of or treatment for metastatic disease
Clinical (e.g. multiple cranial nerve deficits in the absence of obvious radiographic disease to explain symptoms) or radiographic evidence of leptomeningeal disease
Evidence of relapsed disease
Patients must be without evidence of M
Evidence of malignancy within  months of study enrollment; this is defined as clear morphologic, radiologic or molecular evidence of disease; mixed chimerism is allowed at the discretion of the clinician
No evidence of residual disease on scan
No evidence of disease metastatic to bone marrow.
Clinical or radiographic evidence of metastatic disease
Clinical evidence of metastatic (Tb, any N; any T, N-; M) disease
Clinical or radiological evidence of metastatic disease
Patients must be without evidence of residual disease as assessed by their treatment team
No evidence of disease
Patients must have evidence of disease either through elevation of tumor markers or radiologic evidence of disease
Participants with known clinical or radiographic evidence of metastatic CNS disease
No evidence of peritoneal disease on preoperative imaging
Radiographic evidence of metastatic disease
No evidence of metastatic disease
Has no evidence of disease
